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Abstract An assay to characterize plasma human
immunodeﬁciency virus 1 (HIV-1) sequences for patients
with low viral loads was developed by combining the
selective binding of anti-CD44 MicroBeads with a nested
RT-PCR targeting the env C2V4 region. Sequences were
obtained from 10 of 20 HIV? patients who had viral loads
below 48 copies/ml. Sequences derived from plasma were
compared to those from CD14? CD16 ?monocytes and
CD4? T cells. The plasma sequences were most closely
related to those ampliﬁed from monocytes, suggesting that
during successful antiretroviral therapy, the predominant
plasma virus originates from myeloid cells. By character-
izing HIV-1 RNA sequences from 8 ml of plasma while
avoiding multiple steps, which can lead to contamination
and deterioration, this method can help elucidate the viral
forms in patients with therapeutically suppressed HIV-1.
Understanding the source of residual viremia is crucial in
developing approaches for viral eradication.
Introduction
The causative agent of the acquired immunodeﬁciency
syndrome (AIDS) belongs to the family Retroviridae, sub-
family Orthoretrovirinae, genus Lentivirus, species Human
immunodeﬁciency virus 1 (HIV-1). HIV-1 maintains a
residual viremia even when suppressed by a highly active
antiretroviral therapy (HAART) regimen to below the clin-
ical detection limits (commonly designated as being a viral
load of\50 copies/ml). If therapy becomes ineffective or is
discontinued, a small number of latently-infected cells can
lead to viral rebound [1–7]. The dynamics and the source of
this persistencyhave only been partly clariﬁed. Probably the
most accepted mechanism of persistence is the existence of
viral reservoirs in latent and stably infected CD4? T cells
[8–10]. Cryptic viral replication may also continue in
immunologically and pharmacologically restricted sites,
such as the brain and testes [7]. This persistence represents a
signiﬁcant challenge for the development of a strategy for
viral eradication.
In order to understand the nature of this residual viremia,
amajorobstacleneedstobeovercome:developingareliable
and consistent method to characterize the residual HIV in
plasma when viral loads are low and below the limits of
quantitation. Previous studies have shown that obtaining
sequences for analysis is challenging because of the extre-
mely low concentration of plasma HIV RNA in patients
under suppressive HAART [11–19]. In cases where plasma
clone sequences have been successfully obtained and char-
acterized, the ﬁndings can help elucidate viral dynamics
under HAART suppression [18, 20–22]. One of the obsta-
cles identiﬁed is the diversity of the virus [23] resulting in
primer mismatch and poor RT-PCR ampliﬁcation.
Ultracentrifugation followed by RT-PCR ampliﬁcation
has often been used to obtain these sequences, but these
C. A. Lopez   M. Vazquez   M. D. Hill   M. Del C. Colon  
T. Porrata-Doria   E. Lorenzo (&)
Molecular Virology Laboratory, Department of Physiology
and Pharmacology, Ponce School of Medicine, P.O. Box 7004,
Ponce, PR 00732, USA
e-mail: lorenzoe@niaid.nih.gov
M. D. Hill
e-mail: mhill@psm.edu
I. C. D. Johnston
Miltenyi Biotec GmbH, Friedrich-Ebert-Str. 68,
51429 Bergisch Gladbach, Germany
Present Address:
E. Lorenzo
Scientiﬁc Review Program, AIDS Research Review Branch,
NIAID, Division of Extramural Activities (DEA),
6700B Rockledge Dr., Room 3134, Bethesda,
MD 20892-7616, USA
123
Arch Virol (2010) 155:895–903
DOI 10.1007/s00705-010-0659-3methods need large volumes of plasma, and the extended
process results in deterioration of the viral material. It has
been demonstrated that the elimination of the pre-extrac-
tion ultracentrifugation step improved nucleic acid yield
and purity to allow genotyping [24]. This study describes a
technique that involves reduced processing time, simple
isolation and a modest volume of plasma (8 ml). This was
achieved by combining the techniques of speciﬁc magnetic
isolation of HIV virions and ampliﬁcation with primers
targeting a stable region in the viral RNA sequence directly
in a viral lysate. No RNA puriﬁcation step was necessary.
The utility of this technique was tested by examining the
cellular source of the low-level viremia in two patients.
Our isolation protocol employs magnetic labeling using
the binding of anti-CD44 MicroBeads (lMACS VitalVirus
HIV Isolation Kit, Miltenyi Biotec, Germany). The budding
virion incorporates cell membrane markers into its envelope
[25], which can be used as a means of binding virions for
collectionandconcentration[26–29].CD44hasbeen shown
to colocalise at the site of HIV budding from the cell
membrane in T cell and monocyte cell lines [30, 31]. These
ﬁndings have been extended to acutely infected cells and
latently-infected cells that were reactivated to induce HIV
production [26]. Indeed, CD44 appears to be upregulated
following mitogenic HIV reactivation in cell lines [31]. The
CD44 molecule may also assist the virus in trafﬁcking to
lymphoidtissues[25,32].HIV-1RNAcaptureefﬁciencyfor
the lMACS CD44 MicroBeads from a variety of patient
samples has been shown to average at least 60% [29], while
efﬁciency of capture from spiked virus/ cell culture super-
natants approaches 100% (unpublished observations).
Recently, anti-CD44 MicroBeads have also been shown to
increase HIV infectivity in culture dramatically [33].
In the study presented here, the isolated HIV-1 RNA
was ampliﬁed by polymerase chain reaction (PCR) using a
nested approach with primers that target the env gene
sequence. Studies have demonstrated that the areas before
the V3 region and after the V4 region are relatively con-
served and homogeneous both within a patient sample and
between patients [34, 35]. At the same time, the sequences
within the C2V4 region undergo rapid diversiﬁcation,
making this area useful for phylogenetic reconstructions of
viral evolution [36–40]. Furthermore, the elucidating
sequences from the C2V4 region can help determine
tropism and immune escape.
Materials and methods
Study subjects
Twenty HIV-positive men and women receiving a
successful HAART regimen (suppressed viremia to
\48 copies/ml for at least 1 year) were enrolled from two
immunological clinics in Puerto Rico and donated blood for
this study. Demographic data and CD4 counts are presented
inTable 1.Sampleswereprocessedwithin2 hofcollection.
The plasma was separated from the cellular components by
centrifuging blood at 3,500 rpm for 15 min. Plasma HIV-1
viral loads were determined by clinical ultrasensitive
Amplicor HIV-1 Monitor Test (quantiﬁcation limit, \48
copies/ml,RocheDiagnosticsSystems),andtheviralloadin
allpatients wasbelowthe limitsofquantiﬁcation.Duetothe
sensitivity of this quantitation assay, ‘‘below detection’’
refers to samples containing\48 virions/ml.
HIV-1 plasma RNA isolation
HIV-1 RNA was isolated from plasma using a modiﬁed
version of the lMACS VitalVirus HIV Isolation Kit
(Miltenyi Biotec GmbH, Germany). The reagents used in
this protocol were those contained in the kit, including the
anti-CD44 MicroBeads, the equilibration buffer (EqB) and
the viral wash buffer (VWB). HIV-1 virions present in the
patient plasma were magnetically labeled by mixing 200 ll
of anti-CD44 MicroBeads and 8 ml of plasma in a 15-ml
conical tube and incubating for 1 h at room temperature.
The sample was centrifuged at 5,000g for 1 min to con-
solidate any plasma remaining in the lid and the walls of
the tube. A MACS l Column (included in the kit) was
Table 1 Patient demographics and health
Patient ID Sex/age CD4 count
(per mm
3)
Months since
diagnosis
1 F/36 988 156
2 F/41 505 132
3 F/42 650 192
4 F/46 504 168
5 F/57 845 204
6 M/51 347 204
7 M/39 439 132
8 M/23 500 36
9 M/47 769 120
10 F/47 348 168
11 F/39 616 120
12 M/50 512 216
13 M/67 560 192
14 M/42 758 144
15 F/44 397 180
16 M/56 175 192
17 M/32 410 96
18 M/46 710 156
19 M/52 339 180
20 F/47 638 108
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123placed in the lMACS separator, equilibrated with 100 ll
EqB and washed three times with 100 ll VWB containing
0.5% BSA. The plasma containing the labeled virions was
added to the l Column 1-ml at a time. The column was
washed twice with 200 ll VWB, removed from the mag-
netic stand and placed above a 1.5-ml microtube. The
magnetically labeled virions were lysed within the column,
and viral RNA contained in the viral lysate was eluted in
two steps. First, 100 ll of lysis buffer (50 mM Tris, pH 8.4,
0.5% Igepal) were added and incubated for 1 min. Then,
another 100-ll aliquot of lysis buffer was added, and using
a 5-ml syringe plunger, pressure was applied to the column
to elute the entire sample. The eluate was immediately
placed at -20 to preserve the isolated plasma HIV-1
RNA.
Cell isolation
Peripheral blood mononuclear cells (PBMC) were sepa-
rated from the other cell components by density gradient
sedimentation on Histopaque-1077 (Sigma-Aldrich,
St. Louis, MO). CD14? CD16? monocytes were separated
from fresh PBMC by using a combination of CD14 and
CD16 monoclonal antibodies (BD Biosciences, San Jose,
CA), and CD4? T cells were separated using CD3 and
CD4 monoclonal antibodies (BD Biosciences). The cells
were sorted in a FACST Calibur Aria (BD Biosciences).
Based on ﬂow cytometry, the isolated monocyte and T cell
suspensions yielded average purities of 95 and 98%,
respectively, using FACSCalibur and CellQuest software
(BD Biosciences). Genomic DNA was isolated from
monocytes and CD4? T cells using a QIAmp DNA Micro
Kit (QIAGEN, Inc, Valencia, CA).
Nested RT-PCR HIV-1 env RNA ampliﬁcation
The isolated HIV-1 env RNA was ampliﬁed by reverse
transcriptase polymerase chain reaction (RT-PCR) using a
OneStep RT-PCR Kit and HotStar Taq DNA Polymerase
(QIAGEN, Inc). An RNA template volume of 40 ll was
used for the primary reaction. The C2V4 region ampliﬁ-
cation was performed with the primers ED31 (forward) and
ED12 (reverse) (Table 2)[ 39]. The conditions of the pri-
mary phase (RT-PCR) were 1 cycle of 50 for 30 min, 95
for 16 min, 60 or 58 for 1 min, and 72 for 2.5 min; 35
cycles of 95 for 30 s, 60 or 58 for 45 s and 72 for
1 min; 1 cycle of 72 for 10 min and hold at 4. For the
second phase (PCR), 1 ll of product was used along with
CV3 (forward and reverse) primers (Table 2)[ 39]. The
conditions for the secondary-phase nested PCR were 1
cycle of 95 for 15 min, 51,4 9  or 45 for 1 min and 72
for 2.5 min; 35 cycles of 94 for 30 s, 51,4 9  or 45 for
45 s and 72 for 1 min; 1 cycle of 72 for 10 min and hold
at 4. The resulting amplicon (525 bp) was electrophoresed
along with a low-molecular-weight marker in 1.2% agarose
and stained with ethidium bromide. To minimize the PCR
error rate, a single positive PCR was used to generate
multiple clones for sequencing.
Cloning and sequencing of C2V4
PCR products were cloned into the pCR 2.1 vector
(Invitrogen, Carlsbad, CA) using the TOPO TA Cloning
Kit (Invitrogen, Carlsbad, CA) according to the manufac-
turer’s speciﬁcations. The recombinant vector was intro-
duced into One Shot Chemically Competent E. coli
(Invitrogen Corp) and ampliﬁed, and the plasmid DNA was
puriﬁed using a QIAprep Spin Miniprep Kit (QIAGEN,
Inc). M13 plasmid primers [41] were used to sequence the
clones in an Applied Biosystems 3130xl Genetic Analyzer
(Applied Biosystems, Foster City, CA).
Analysis of sequences
Alignment of the nucleotide sequences was conducted
using the CLUSTAL W application [42, 43] integrated in
the BioEdit version 7.0.5.2 [44] and then edited by hand.
The pairwise nucleotide distance calculations for plasma-
derived sequences were performed using MEGA 4 [45]
employing the Kimura 2-parameter method [46]. For the
intrapatient analysis of sequences derived from plasma,
CD14? CD16? monocytes and CD4? T cells, the pair-
wise distance calculations were performed as described
above but by using the Maximum Composite Likelihood
Table 2 Primer sequences and gene location
Primer ID Sequence 50–30 Genome location
ED31 CCTCAGTCATTACACCAGGCCTGTCCAAAG 6817–6846
ED12 AGTGCTTCCTGCTGCTCCCAAGAACCCAAG 7782–7811
CV3-F CTGTTAAATGG CAGTCTAGC 7002–7021
CV3-R TGATGGGAGGGGTATACATT 7523–7542
Primers used in the nested RT-PCR for the ampliﬁcation of the env gene C2V4 region. The gene location is based on the HIV-1 HXB2 genome.
(GenBank accession number K03455)[ 49]
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phylogenetic tree of 1,000 bootstrapped data sets [47],
which was constructed by the neighbor-joining method
[48], assuming a transition/transversion rate of 2.0. The
C2V4 segment of the reference sequence HIV-1 HXB2
(GenBank accession number K03455)[ 49] was used as an
outgroup (gene location 7002–7400). A position-speciﬁc
scoring matrix was used to analyze the genetic tropism of
the plasma-derived HIV-1 V3 region sequences (Web-
PSSM) [50].
Results
Method performance
Duplicate sample volumes of 8 ml per patient were run
under identical conditions. Envelope sequences from 10
out of 20 patients were successfully characterized, repre-
senting a success rate of 50%. Details of the patient sam-
ples are listed in Table 3, including detectability of viral
RNA and success of viral genotyping.
To better assess the sensitivity of the test, the samples
were divided in two groups. Group A samples were clas-
siﬁed as ‘‘below 48 copies/ml’’ for those with an obser-
vable ampliﬁcation of virus during quantitation and Group
B were classiﬁed as ‘‘nondetected’’ for those for whom no
ampliﬁcation was detected. In Group A, HIV-1 plasma
RNA from 5 out of 8 samples (62.5%) could be charac-
terized, while in Group B, characterization was successful
in 5 out of 12 samples (41.7%) (Table 3).
Evolutionary history reconstruction
Evolutionary history of the HIV-1 viral forms from the
characterized plasma samples was inferred using the phy-
logeny of env gene sequences. The inferred phylogenetic
tree (Fig. 1) showed that the plasma sequences from all
patients clustered separately with 100% bootstrap values.
This ﬁnding greatly diminishes the possibility of laboratory
contamination.
Phylogenetic analysis of the characterized HIV-1 RNA
sequences
The existence of different quasispecies within the same
patient is a well-recognized characteristic of HIV-1 [51].
The intrapatient analysis showed a genetic variability with
nucleotide distances between 0–4.2%, which is consistent
with a homogeneous infection or could represent resam-
pling among patients with few target virions. In contrast,
the interpatient analysis presented high variability between
all patients (10–20%). The divergent nucleotide distances
are also consistent with separate sources for the viral forms
from each patient and speak against contamination.
An analysis of predicted tropism was performed using
the sequences from the plasma virions. Five of these
patients had CCR5 viruses, three had CXCR4, and the
other two had both forms. Disabling mutations, either
frameshifts or stop codons, appeared in at least one clone
from two patients.
Analysis of intrapatient sequences from plasma,
CD14? CD16? monocytes and CD4? T cells
A small pilot project was undertaken in order to test the
utility of the assay. The assay was employed to examine the
sources ofresidualviremia intwo patients, numbers 5and 6.
In addition to the characterization of circulating plasma
virus,integratedprovirussequenceswereanalyzedfromtwo
blood cell populations: CD4? T cells and CD14? CD16?
monocytes.CD14?CD16?areaminoritysetofmonocytes
thathavebeenshowntoexpresstheHIVcoreceptorCCR5at
a high level [52]. The phylogenetic reconstruction was
Table 3 Quantitation and characterization of patient plasma samples
Sample ID Viral quantity (copies/ml) Characterized? Sample ID Viral quantity (copies/ml) Characterized?
P1 ND No P11 \48 Yes
P2 ND No P12 ND No
P3 \48 Yes P13 ND No
P4 ND Yes P14 ND No
P5 ND Yes P15 ND Yes
P6 \48 Yes P16 \48 Yes
P7 \48 No P17 \48 Yes
P8 \48 No P18 ND Yes
P9 ND No P19 \48 No
P10 ND No P20 ND Yes
Samples characterized and not characterized are shown with their respective viral quantitation results
P patient, ND HIV-1 RNA not detected,\48 less than 48 HIV-1 RNA copies per milliliter of plasma
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123performed as described above, using the maximum com-
posite likelihood substitution model. The inferred phyloge-
netic tree is presented in Fig. 2.
Pairwise distance calculations showed minimal vari-
ability between cloned sequences derived from the same
source (\0.6%) in both patients. This could have been due
to a homogenous infection or resampling from a small pool
of virions. The exception was the CD4? T cells sequences,
which showed differences (0–6.2%) indicating heteroge-
neous infection. The comparison between sources showed
a closer relationship between plasma and CD14? CD16?
monocytes in both patients. For patient 5, nucleotide dif-
ferences were observed when comparing plasma versus
monocytes (0–1.5%), plasma versus CD4? T cells (9–
9.7%), and monocytes versus CD4? T cells (8.5–8.7%). In
patient 6, the observed distances were 0–1.7% for plasma
versus monocytes, 2.9–5.1% for plasma versus CD4? T
cells, and 2.9–4.3% for monocytes versus CD4? T cells.
Discussion
It is well established that residual HIV-1 viremia can
continue after long-term adherence to antiretroviral therapy
and the resulting increase in the capacity of the body to
defend itself. In this setting, the virus resides in reservoirs
of long-lived cells or ﬁnds cryptic places to hide, evading
therapeutic and immunologic pressures. Few studies have
characterized plasma HIV-1 RNA sequences in patients
with viral loads below 48 copies/ml [11, 17, 18, 22, 23,
53]. The method presented here has several advantages
over other methods. It requires a lower volume of blood
than most, it requires less sample processing, it has a
comparable rate of success, and it ampliﬁes the C2V4
region of the envelope, an area that is important for
determining tropism and tracking viral evolution and
immune escape.
The most utilized approach was developed by Bailey
and colleagues in 2006 [23]. Their team collected 17 ml of
blood per visit during a period of intensive sampling (every
2–3 days for 36 closely spaced visits). A total of 6–8 ml of
plasma was ﬁltered and ultracentrifuged at 25,2009g for
2 h at 4C to pellet the sample virions. Viral RNA was
isolated using the QIAamp Viral RNA Kit (Qiagen) silica
membrane binding method, and the protease and RT genes
were ampliﬁed in seven different RT-PCR reactions. One
of the study’s difﬁculties was the necessity for intensive
sampling to recover the plasma. Also, they did not amplify
the env gene, so tropism studies could not be performed on
the characterized sequences.
McClernon et al. [24], using silica columns, were able to
obtain sequences from 75% of samples that had 100–
500 virions/ml, and in one iteration of their method, 30%
success for samples 50–500 virions/ml. These were with
spiked samples of a homogenous viral form, in contrast to
our study using diverse virus found in patients. Using a
quantiﬁable viral load, McClernon et al. were able to assess
viral recovery rate; we were not.
The goal of this study was to develop an assay that can
reliably recover viral material while using less plasma
volume and which would allow processing the sample in a
shorter period of time. With a 50% success rate, this study
has shown that plasma HIV-1 RNA can be genetically
characterized in samples with viral detection values of
\48 copies/ml while reducing both the sample volume and
the process time. The assay tended towards a higher rate of
characterization in samples with viral detection values of
\48 copies/ml (62.5%) when compared to samples with
no detectable HIV-1 RNA (41.7%).
The isolation of virus by the method described here
requires capture using CD44 selection. CD44 is involved in
lymphocyte homing, is expressed on many cell types,
including both lymphocytes and macrophages [54], and is
one of the host molecules most frequently incorporated by
the budding HIV-1 [26]. Using CD44 reactivity, recovery
of 60% of HIV-1 in patient samples has been demonstrated
Fig. 1 Phylogenetic reconstruction for the assay performance assess-
ment. The evolutionary history of the validation sequences was
reconstructed in a phylogenetic tree. Neighbor joining was used with
the Kimura 2-parameter method in 1,000 bootstrapped replications.
The HIV-1 HXB2 sequence (gene location 7002–7400) was used as
an outgroup (GenBank accession number K03455). The sample ID is
represented by the letter P (patient) and a number. The number after
the dash corresponds to the clone number. The scale is at a 2%
nucleotide difference
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do not bear CD44.
Other cell-surface markers may be useful in collecting
and concentrating the virus; however, the presence of a
molecule does not guarantee efﬁcient acquisition. While
the capture of HIV by HLA-DR was shown to be efﬁcient
from primary T cells and monocytes infected in cell culture
[26], these molecules were less efﬁcient than CD44 for
capture of HIV from clinical samples [27, 28]. Other
possibilities are intriguing. ICAM-1 increases the efﬁ-
ciency of HIV-1 infection [55] and could provide insights
into speciﬁc forms of the virus. However, this work was
done in cultured cell lines. Still, the efﬁciency of the iso-
lation of HIV particles from patient samples using LFA-1
(CD18 /CD11a), CD63, ICAM-1 or HRS has not been
experimentally assessed. For now, CD44 appears to be the
Fig. 2 Phylogenetic
reconstruction of HIV-1 env
nucleotide sequences from
CD4? T cells, CD14? CD16?
monocytes, and plasma isolates
of samples P5 and P6.
Evolutionary reconstruction of
the plasma-derived HIV-1 env
sequence was generated using
neighbor joining with the
Kimura 2-parameter method.
Numbers between branch nodes
represent bootstrap values
(1,000 replicates). a Patient 5,
b patient 6. Samples are
distributed as follows: closed
squares monocytes; open
triangles CD4? T cells; open
circles plasma; closed diamonds
outgroup (HXB2, GenBank
accession number K03455). The
number of substitutions per site
is indicated by the distance bar
shown at the bottom
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123best choice for efﬁcient capture of HIV from patient
samples.
This represents the ﬁrst time that success has been
achieved in acquiring sequences from patient plasma
samples containing viral loads below 48 copies/ml without
applying ultracentrifugation to the plasma sample—a step
that can degrade the viral material. The virus isolated from
each patient was unique, as demonstrated by the separate
clusters in the phylogenetic trees and the high bootstrap
values, thus diminishing the possibility of contamination.
Further analysis of the data showed that plasma viral
forms are derived from more than one source. This ﬁnding
supports the theory that residual viremia is derived not only
from resting CD4? T cells but also from another reservoir
[7].
Most monocytes have a low expression of CD16 and
CCR5 and have been shown not to harbor HIV-1. In con-
trast, the relatively smaller proportion of monocytes that
are CD14? CD16?, which make up only 5–15% of the
monocyte population, express CCR5 to a much higher
degree [56]. Ellery et al. [57], have shown that monocytes
that express CD16 are much more permissive to HIV-1
infection in vivo and in vitro.
In two of the patients, speciﬁc cell types (CD4? T cells
and CD14? CD16? monocytes) were examined as
potential viral sources. An evolutionary history was then
reconstructed using nucleotide sequences from plasma,
CD4? T cells and monocytes. HIV-1 env plasma sequen-
ces were shown to be more related to provirus sequences
present in CD14? CD16? monocytes than in resting
CD4? T cells. This agrees with data suggesting that HIV-1
derived from a cell of a myeloid lineage predominates in
the plasma of patients receiving effective antiretroviral
therapy [23] and with the above-cited ﬁndings of Ellery
et al. [57]. None of the viral forms from the plasma of these
two patients had disabling mutations. Other unsampled cell
populations could be the source of the plasma virus,
including tissue-associated macrophages. The viral forms
in a majority of the patients in the plasma sequences study
were macrophage tropic or dual tropic.
Several of the positive samples had only one viral form.
This could be due to resampling and makes the lack of
diversity suspect. In this study, with samples below quan-
tiﬁcation levels, it is possible that very few virions were
present, making the problem of resampling more acute.
Kearney et al. [58] introduced a method for obtaining
sequences from single virions. This method, however,
began with sample dilution from a higher, measurable viral
load.
Subsequent studies are required to determine the pro-
cesses involved in viral replication and viral production in
infected individuals when the plasma levels are below
48 copies/ml. This information can give the scientiﬁc and
clinical community the opportunity to develop new
approaches to create better eradication strategies.
In conclusion, the developed genotypic assay showed
success in the characterization of HAART-suppressed
plasmaHIV-1RNAinhalfofthepatientswhilereducingthe
amount of sample needed and the processing time. This
method can be used to illuminate the residual viral forms in
patients with low levels of virus and those classiﬁed as elite
controllers.
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